Use of Intravesical Chemotherapy in the US Following Publication of a Randomized Clinical Trial
Open Access
- 1 March 2022
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (3) , e220602
Abstract
Recurrence of low-grade bladder cancer is common.1 Intravesical chemotherapy (eg, mitomycin C or epirubicin) administered after transurethral resection of bladder tumor (TURBT) has been shown to be associated with decreased recurrence and is guideline recommended; however, rates use are low.2-4 To that end, the Southwestern Oncology Group (SWOG) S0337 randomized clinical trial (RCT), published in May 2018,5 sought to expand the urologist’s armamentarium by demonstrating the efficacy of post-TURBT intravesical gemcitabine. The authors of the RCT cite the drug’s lower cost, wider availability, and milder toxicity relative to mitomycin C as advantages.5 Whether these findings have increased rates of post-TURBT chemotherapy use is unknown. Additionally, since the trial did not compare gemcitabine directly to other historically used agents, the extent to which gemcitabine has supplanted these drugs is uncertain.Keywords
This publication has 6 references indexed in Scilit:
- Improving Rates of Immediate Postoperative Intravesical Chemotherapy with Gemcitabine for Low-Grade Bladder Cancer: An Implementation AnalysisUrology Practice, 2022
- Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor RecurrenceJAMA, 2018
- Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO GuidelineJournal of Urology, 2016
- Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa–pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?European Urology, 2016
- National Practice Patterns for Immediate Postoperative Instillation of Chemotherapy in Nonmuscle Invasive Bladder CancerJournal of Urology, 2012
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006